Search Results | DrugBank Online

Displaying drugs 13401 - 13425 of 15170 in total

EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.

Investigational

Matched Description: … enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and …

AdPEDF

AdPEDF is under development for the treatment of wet age-related macular degeneration (AMD). It has been shown to rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and cause abnormal blood vessels to regress while protecting the eye’s photoreceptors.

Investigational

Matched Description: … rapidly elevate the intraocular AdPEDF protein levels in the eye, inhibit abnormal blood vessel growth, and …

RUS 3108

RUS 3108 is being developed for the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and stroke by Dr. Reddy’s Laboratories. The drug’s Phase I clinical trials have been initiated in Europe to assess safety of the drug compound in healthy volunteers.

Investigational

Matched Description: … the treatment of atherosclerosis, the major cause of cardiovascular disorders such as heart attacks and …

VY-HTT01

VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression. VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.

Investigational

Matched Description: … VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses …

ABX1100

ABX1100 is an investigational Centyrin-siRNA conjugate that targets the Gys1 gene, which encodes glycogen synthase 1 (Gys1), an enzyme that is responsible for glycogen synthesis in the muscle. It was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease.

Investigational

Matched Description: … It was first developed by Aro Biotherapeutics and is being investigated for the treatment of Pompe disease …

Advanced Filter

Filter by Group

Filter by Market Availability

Talampicillin

EHT899

AdPEDF

RUS 3108

VY-HTT01

ABX1100

2-Phenethyl-2,3-Dihydro-Phthalazine-1,4-Dione

3-Chloro-9-Ethyl-6,7,8,9,10,11-Hexahydro-7,11-Methanocycloocta[B]Quinolin-12-Amine

5-[3-(2,5-dimethoxyphenyl)prop-1-yn-1-yl]-6-ethylpyrimidine-2,4-diamine

PQ-10

3-(4-Fluorophenyl)-1-Hydroxy-2-(Pyridin-4-Yl)-1h-Pyrrolo[3,2-B]Pyridine

Gluco-Phenylimidazole

Cyanocinnoline

2-Aminoquinazolin-4(3h)-One

(9S)-9-[(8-AMMONIOOCTYL)AMINO]-1,2,3,4,9,10-HEXAHYDROACRIDINIUM

(2,6-Dimethylphenoxy)acetic acid

N-(2,6-dimethylphenyl)-5-phenylimidazo[1,5-a]pyrazin-8-amine

Cadralazine

REP8839

4-Hydroxy-1,2,5-oxadiazole-3-carboxylic acid

(2R,3R,4R,5R)-3,4-Dihydroxy-N,N'-bis[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-2,5-bis(2-phenylethyl)hexanediamide

3,4-Dihydro-2h-Pyrrolium-5-Carboxylate

Sri-9662

7-cyano-7-deazaguanine

4-oxo-4,5-dihydro-1,2,5-thiadiazole-3-carboxylic acid